Holen Sie sich die Stockscreener-App
2.09
3.98%
0.08
Handel nachbörslich:
2.09
Schlusskurs vom Vortag:
$2.01
Offen:
$2.03
24-Stunden-Volumen:
131.72K
Relative Volume:
0.87
Marktkapitalisierung:
$35.95M
Einnahmen:
$276.00K
Nettoeinkommen (Verlust:
$-6.09M
KGV:
-1.8496
EPS:
-1.13
Netto-Cashflow:
$-5.99M
1W Leistung:
-9.52%
1M Leistung:
-24.28%
6M Leistung:
-33.65%
1J Leistung:
+59.55%
1-Tages-Spanne:
$1.97
$2.12
1-Wochen-Bereich:
$1.95
$2.42
52-Wochen-Spanne:
$1.20
$6.85
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Firmenname
Lexaria Bioscience Corp
Sektor
Branche
Telefon
250-765-6424
Adresse
100 - 740 MCCURDY ROAD, KELOWNA
Vergleichen Sie LEXX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| LEXX | 2.09 | 35.95M | 276.00K | -6.09M | -5.99M | -1.13 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Lexaria Bioscience Corp Aktie (LEXX) Neueste Nachrichten
LEXXWLexaria Bioscience Corp. Warrant Latest Stock News & Market Updates - StockTitan
Invenomic Capital Management LP Adjusts Stake in Lexaria Bioscie - GuruFocus.com
Lexaria commences unique drug distribution study - Investing.com
Lexaria Launches Groundbreaking Semaglutide Study vs. Rybelsus Formulation | LEXX Stock News - StockTitan
LEXXLexaria Bioscience Corp. Latest Stock News & Market Updates - StockTitan
Lexaria's DehydraTECH Diabetes Study Advances: FDA-Track Phase 1b Trial Gets Key Approval | LEXX Stock News - StockTitan
Lexaria Bioscience Corp. (LEXX) Quarterly 10-Q Report - Quartzy
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments - Yahoo Finance
Lexaria Positions DehydraTECH Platform in Booming $471B GLP-1 Drug Market | LEXX Stock News - StockTitan
Lexaria reports promising blood sugar control in animal study - Investing.com India
Lexaria reports promising blood sugar control in animal study By Investing.com - Investing.com Australia
Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study - StockTitan
Lexaria reports advances in weight loss drug study - Investing.com India
Lexaria reports advances in weight loss drug study By Investing.com - Investing.com UK
Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study - StockTitan
Lexaria Bioscience : Corporate Presentation - Marketscreener.com
Lexaria Bioscience Corp. sets date for combined annual and special meeting - Investing.com India
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
Lexaria Bioscience : Registered Direct Offering Form 8 K - Marketscreener.com
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - StockTitan
Companies Like Lexaria Bioscience (NASDAQ:LEXX) Are In A Position To Invest In Growth - Yahoo Finance
Lexaria Bioscience announces $5M securities offering - MSN
Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - StockTitan
Lexaria to test DehydraTECH GLP-1 product for weight loss, diabetes - MSN
Lexaria starts pilot study for oral diabetes treatment By Investing.com - Investing.com South Africa
Lexaria starts pilot study for oral diabetes treatment - Investing.com
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing - StockTitan
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing | LEXX Stock News - StockTitan
Lexaria Foresees Lead in Booming GLP-1 Market - TipRanks
Lexaria Updates Current GLP-1 Market - Yahoo Finance
Why Lexaria Bioscience (LEXX) Shares Are Moving - MSN
Lexaria Bioscience appoints new CFO Michael Shankman - Investing.com
Lexaria Bioscience appoints new CFO Michael Shankman By Investing.com - Investing.com Canada
Lexaria Bioscience appoints new CFO amid growth plans By Investing.com - Investing.com Australia
Lexaria Bioscience appoints new CFO amid growth plans - Investing.com
Lexaria Bioscience Welcomes New CFO Amid Growth - TipRanks
Lexaria Bioscience Corp. Appoints Michael Shankman as Chief Financial Officer - Marketscreener.com
Lexaria Advances Oral Diabetes Treatment Study - TipRanks
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3 - StockTitan
Stocks of Lexicon Pharmaceuticals Inc (LXRX) are poised to climb above their peers - SETE News
XTX Topco Ltd Raises Stock Holdings in Lantronix, Inc. (NASDAQ:LTRX) - Defense World
Victory Capital Management Inc. Acquires 13,972 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Defense World
Great Point Partners LLC Purchases New Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Defense World
Understanding LXRX’s book value per share for better investment insights - US Post News
Upward Trajectory: Lexicon Pharmaceuticals Inc (LXRX) Posts a Slidee, Closing at 1.58 - The Dwinnex
Light & Wonder price target lowered to $90 from $92 at Susquehanna - TipRanks
Bearish block trade of LIFETECH SCI(01302) 1.3M shares at $1.5, $1.95M turnover - AASTOCKS.com
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating ‘More Effective, Tolerable’ Oral Delivery of GLP-1 Drugs - MSN
Why Is Lattice Semiconductor (LSCC) Stock Rocketing Higher Today By Stock Story - Investing.com Canada
Financial Analysis: Lexaria Bioscience (NASDAQ:LEXX) & Xeris Biopharma (NASDAQ:XERS) - Defense World
Lexaria (NASDAQ: LEXX) Eyeing Market Potential with Unique Delivery Platform, GLP-1 Program - Barchart
Finanzdaten der Lexaria Bioscience Corp-Aktie (LEXX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):